Nextage Therapeutics (Israel) Top Management
| NXTG Stock | ILA 101.10 2.60 2.51% |
Analysis of Nextage Therapeutics' management performance can provide insight into the company performance.
| Abraham Dreazen Insider Chief Officer |
Nextage |
Nextage Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.7891) % which means that it has lost $0.7891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.4931) %, meaning that it generated substantial loss on money invested by shareholders. Nextage Therapeutics' management efficiency ratios could be used to measure how well Nextage Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Nextage Therapeutics Workforce Comparison
Nextage Therapeutics is considered to be number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 19,199. Nextage Therapeutics adds roughly 65.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Nextage Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Nextage Therapeutics Price Series Summation is a cross summation of Nextage Therapeutics price series and its benchmark/peer.
Nextage Therapeutics Stakeholder
| Abraham Dreazen | Chief Officer | Profile |
About Nextage Therapeutics Management Performance
The success or failure of an entity such as Nextage Therapeutics often depends on how effective the management is. Nextage Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nextage management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nextage management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. The company was formerly known as Micromedic Technologies Ltd and changed its name to Nextage Therapeutics Ltd in August 2020. NEXTAGE THERAPEUTI operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.
Please note, the presentation of Nextage Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nextage Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Nextage Therapeutics' management manipulating its earnings.
Nextage Therapeutics Workforce Analysis
Traditionally, organizations such as Nextage Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nextage Therapeutics within its industry.Nextage Therapeutics Manpower Efficiency
Return on Nextage Therapeutics Manpower
| Revenue Per Employee | 1.4K | |
| Net Loss Per Employee | 118.9K |
Complementary Tools for Nextage Stock analysis
When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |